ABSTRACT
Molecular biology techniques have fundamentally transformed the landscape of drug development, because they have allowed a much deeper understanding of the molecular underpinnings of diseases, thus leading to more targeted and effective therapeutic approaches. Techniques such as gene sequencing, genome editing, and proteomics play a crucial role in identifying novel drug targets and understanding disease mechanisms at the molecular level. In particular, CRISPR-Cas9 and RNA interference (RNAi) become significant tools for functional genomics and drug-target validation, among others. In this respect, high-throughput screening technologies have significantly improved the efficiency and scope of drug discovery processes, allowing, at an accelerated velocity, the identification of leads to be further developed as chemical drugs. In preclinical research, molecular diagnostics and genetically engineered animal models are critical for assessing the safety and efficacy of new drugs, providing insights into their potential clinical application. Despite these advancements, challenges such as technical limitations, high costs, and ethical concerns remain significant obstacles to widespread implementation. However, trends like artificial intelligence (AI), machine learning, and multi-omics approaches are slowly mitigating the above issues by making data analysis more efficient, allowing drugs to be targeted more precisely, and improving the overall efficiency of drug discovery. These technologies are envisioned to speed up personalized medicine and provide more customized therapies according to the genetic predisposition of the patients. Ultimately, molecular biology techniques play an irreplaceable role in drug development, and any future research in this field may lead to breakthroughs in therapeutic options and improvements in patient care for a broad range of diseases.
